Dexcom (DXCM) Operating Leases (2019 - 2026)

Dexcom (DXCM) has 8 years of Operating Leases data on file, last reported at $69.0 million in Q1 2026.

• Quarterly Operating Leases rose 15.58% year-over-year to $69.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.0 million (up 15.58% YoY) and the FY2025 annual result came in at $73.4 million, up 12.92% from the prior year.
• Operating Leases retreated to $69.0 million in Q1 2026 per DXCM's latest filing, from $73.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $94.6 million in Q4 2022 and bottomed at $50.6 million in Q3 2025.
• The 5-year median for Operating Leases is $76.8 million (2024), against an average of $76.1 million.
• The widest annual swing landed in 2025, when Operating Leases dropped 28.83%; it then gained 15.58% in 2026.
• Tracing DXCM's Operating Leases over 5 years: stood at $94.6 million in 2022, then retreated by 15.33% to $80.1 million in 2023, then dropped by 18.85% to $65.0 million in 2024, then increased by 12.92% to $73.4 million in 2025, then declined by 5.99% to $69.0 million in 2026.
• Per Business Quant, the three latest DXCM Operating Leases figures stand at $69.0 million (Q1 2026), $73.4 million (Q4 2025), and $50.6 million (Q3 2025).

Peer Comparison